Investor Presentation 2012 2017 2018 Q4 2020 2021 Ted Karkus, CEO, restructures Sold the Cold-EEZE cold remedy From 2018 to 2022 we delivered We commenced CLIA lab services Acquisition of Nebula Genomics. and turns around the Company. brand for $50m to Mylan shareholder value through and have transitioned from Plan to leverage Food, Drug and Ultimately revenue grew to a Pharmaceuticals. special dividends of$2.40 per COVID-19 testing to genomic Mass distribution and genomic peak of $122 million for the shar ...